EBAMED
18.2.2021 13:02:04 CET | Business Wire | Press release
EBAMed SA, developer of medical technologies to transform the treatment of cardiac arrhythmias, has appointed experienced specialist Marina Izzo as Chief Executive Officer (CEO). Mrs. Izzo will set the vision for EBAMed’s technology and lead the effort for the next financing round, planned for 2022. Former CEO and co-founder, Adriano Garonna has transitioned to Chief Technology Officer (CTO) and maintains a role on the company’s Board of Directors.
“Marina has strong experience in leading medical device businesses and developing the market for groundbreaking cardiovascular technologies in Europe, North America and China,” said Mr. Giovanni Leo, Chairman of the Board. “Her experience will be invaluable as we realize our mission to shift the paradigm in electrophysiology (EP) from catheter-based ablation therapies to non-invasive EP procedures.”
Mrs. Izzo served as CEO for Cardionovum, an innovative developer of drug coated balloon technology. Prior to that, she was Senior Director of Sales and Marketing at Symetis SA (now part of Boston Scientific), where she established the company as a key competitor in the transcatheter aortic valve implantation (TAVI) market. She has held several leadership roles with Medtronic in Europe and with St. Jude Medical, including Marketing Director for the EMEA Atrial Fibrillation (AF) business. Mrs. Izzo is a graduate of Bocconi University of Milan.
“Many patients fail or cannot undergo conventional invasive therapies such as ablation,” said Mrs. Izzo. “I am very excited to continue exploring the potential of radiation oncology therapies in cardiac medicine and to realize EBAMed’s mission to change the lives of patients living with cardiac arrhythmias”.
Some 53 million people globally1 experience some type of cardiac arrhythmia. For older persons with a history of heart disease, arrhythmia can lead to serious medical complications. The development of a radiation therapy approach, combined with an unique motion monitoring and gating solution to improve target definition and tracking accuracy, could be of substantial value in providing alternative therapy to either drug therapy or catheter-based ablation, and to reduce radiation to innocent myocardium.
About EBAMed
EBAMed is an early-stage, private medical device company. EBAMed is developing a cardiac ultrasound product to improve radioablation for Ventricular Tachycardia, a growing clinical need in the face of the prevalence of heart disease, and aging populations. For more information, visit https://eba-med.com
1 JPMorgan 39th Annual Healthcare Conference, January 2021 - Virtual
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005060/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom